Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Castle Biosciences (NASDAQ: CSTL) has presented new data at the 19th European Association of Dermato-Oncology Congress in Rome, highlighting the effectiveness of its DecisionDx®-Melanoma test for patients with stage I cutaneous melanoma (CM). This innovative test enhances risk stratification compared to the traditional AJCC staging, which relies solely on clinical and pathologic factors. Specifically, DecisionDx-Melanoma shows improved recurrence-free survival (RFS) rates of 97.3% for low-risk Class 1A compared to 77.3% for high-risk Class 2B. Additionally, it demonstrates better melanoma-specific survival (MSS) with rates of 98.0% for Class 1A versus 92.3% for Class 2B. Notably, high-risk patients identified by the test were 5.4 times more likely to die from melanoma compared to AJCC-staged patients, indicating the potential of DecisionDx-Melanoma in guiding enhanced clinical care.